- 1. M. CHRISTOPHER ROEBUCKRxEconomics LLC 11350 McCormick Road,
Suite 705 Hunt Valley, MD 21031(410) 215-8380 www.RxEconomics.com
[email protected] SUMMARYHealth Economist with over 15 years of
experience in pharmacoeconomics and health services/outcomes
research. Detail-orientedcritical thinker who successfully
leverages extensive education, advanced quantitative skills, and
rich healthcare background to deriveempirical answers to important
business and societal questions. Adept at operating at the nexus of
academia and private industry,routinely publishing in high-quality
journals, and speaking publically on topics of expertise. Core
competencies lend strength to: Pharmacy benefit design and
optimization Comparative effectiveness research Economic evaluation
of health care programs Health policy and legislation analysis
Predictive modeling of health services use and cost Applied
econometrics, statistics, and analytics Medical/prescription claims
data coding and analysis Translation of scientific research into
business practicePROFESSIONAL EXPERIENCERXECONOMICS LLC, Hunt
Valley, MD2010-PresentPrincipal, Health Economist Provide expert,
applied health economics research consulting services to healthcare
providers, payers, and policymakers. Apply econometric methods in
analyzing claims data to answer critical business questions,
bolster value propositions; and gaininsight into the impact of
pharmacy benefit design on prescription drug use, and the medical
cost savings and productivityenhancements derived from medication
adherence. Advise clients on issues of healthcare reform,
value-based insurance design and purchasing.CVS CAREMARK, Hunt
Valley, MD2002-2011Director, Strategic Research-Health Economist
(2007-2011) Led analytics team in the design and production of
health economics and outcomes research studies including the
evaluation ofpharmacy benefit management products and services, as
well as the comparative effectiveness of pharmacotherapies.
Advanced the science of pharmacy benefit design, Medicare Part D
plan choice, and the value of medication adherence. Rendered
advanced statistics and econometrics methodological coaching and
oversight companywide. Conducted health policy analysis of
legislation and advised executive leadership on expected economic
impacts. Disseminated findings via top-tier, peer-reviewed journal
publication and presentation at industry conferences. Coordinated
collaborations with external academic, plan sponsor, and
manufacturer partners.Manager, Predictive Modeling and Forecasting
(2005-2007) Built and optimized claims-based predictive models of
health services use and cost, also used for risk adjustment.
Employed time-series, data mining, and Monte Carlo simulation
methods for forecasting of key business metrics.Consulting Research
Analyst (2002-2005) Constructed budget impact models of new brand
and generic drug launches for plan sponsor customers. Designed,
sold, executed, and delivered pharmacoeconomics and outcomes
research studies to manufacturer clients. Managed product that
calculated the script-lift and return-on-investment of
direct-to-consumer advertising campaigns.UNIVERSITY OF MIAMI,
SCHOOL OF MEDICINE, Miami, FL1998-2002Senior Research Associate
Performed economic evaluations of public and private substance
abuse and mental health treatment programs using the DrugAbuse
Treatment Cost Analysis Program, Addiction Severity Index, and
Treatment Services Review. Investigated relationships between
substance abuse and health, criminal activity, employment, and
education using advancedeconometric techniques in the analysis of
various public use datasets. Served as Project Director of four
multi-year grants totaling approximately $1 million sponsored by
the National Institute onDrug Abuse, Center for Substance Abuse
Treatment, and Robert Wood Johnson Foundation. EDUCATIONDoctor of
Philosophy Candidate, Public Policy, UMBC, Baltimore, MD, expected
2012.Master of Business Administration, Finance, University of
Miami, Coral Gables, FL, 1997.Bachelor of Arts, Economics,
University of Pennsylvania, Philadelphia, PA, 1994.TECHNICAL
SKILLSEconometrics: endogeneity testing and control using panel
data methods, instrumental variables, and propensity score
matching.Software: STATA (expert), SAS, SPSS, @Risk.
2. M. Christopher RoebuckPage 2 of 2SELECTED
PUBLICATIONSKetcham, J., C. Lucarelli, E. Miravete, and M.C.
Roebuck. In Press. Sinking, Swimming, or Learning to Swim in
Medicare Part D.American Economic Review.Carls, G.S., M.C. Roebuck,
T.A. Brennan, J.A. Slezak, O.S. Matlin, and T.B. Gibson. 2012.
Impact of Medication Adherence onAbsenteeism and Short-Term
Disability for Five Chronic Diseases. Journal of Occupational and
Environmental Medicine 54(7):792-805.Polinski, J.M., W.H. Shrank,
R.J. Glynn, H.A. Huskamp, M.C. Roebuck, and S. Schneeweiss. 2012.
Beneficiaries with Cardiovascular Disease and the Part D Coverage
Gap. Circulation: Cardiovascular Quality and Outcomes 5:
387-395.Roebuck, M.C., J.N. Liberman, M. Gemmill-Toyama, and T.A.
Brennan. 2011. Medication Adherence Leads to Lower Health Care Use
and Costs Despite Increased Drug Spending. Health Affairs
30(1):91-99.Liberman, J.N. and M.C. Roebuck. 2010. Prescription
Drug Costs and the Generic Dispensing Ratio. Journal of Managed
CarePharmacy 16(7): 502-506.Roebuck, M.C. and J.N. Liberman. 2009.
Impact of Pharmacy Benefit Design on Prescription Drug Utilization:
A Fixed Effects Analysis of Plan Sponsor Data. Health Services
Research 44(3): 988-1009.Knealing, T.W., M.C. Roebuck, C.J. Wong,
and K. Silverman. 2008. Economic Cost of the Therapeutic Workplace
Intervention Added to Methadone Maintenance. Journal of Substance
Abuse Treatment 34(3): 326-332.Powers, C.A., C.M. Meyer, M.C.
Roebuck, and B. Vaziri. 2005. Predictive Modeling of Total
Healthcare Costs Using Pharmacy Claims Data: A Comparison of
Alternative Econometric Cost Modeling Techniques. Medical Care
43(11): 1065-1072.French, M.T., M.C. Roebuck, and P.K. Alexandre.
2004. To Test or Not to Test: Do Workplace Drug Testing Programs
ReallyDiscourage Employee Drug Use?" Social Science Research 33(1):
45-63.Roebuck, M.C., M.T. French, and M.L. Dennis. 2004. Adolescent
Marijuana Use and School Attendance. Economics of Education Review
23(2): 145-153.Roebuck, M.C., M.T. French, and A.T. McLellan. 2003.
DATStats: Results from 85 Studies Using the Drug Abuse Cost
Analysis Program (DATCAP). Journal of Substance Abuse Treatment
25(1): 51-57.French, M.T., M.C. Roebuck, and P.K. Alexandre. 2001.
Illicit Drug Use, Employment, and Labor Force Participation."
SouthernEconomic Journal 68(2): 349-368.SELECTED
PRESENTATIONSRoebuck, M.C., G.S. Carls, T.B. Gibson, J.A. Slezak,
J.N. Liberman, and T.A. Brennan. Impact of Medication Adherence on
Worker Productivity: An Instrumental Variables Analysis of Five
Chronic Diseases. Presented at Academy Health Annual Research
Meeting, Seattle, WA, June 13, 2011.Roebuck, M.C. and T.B. Gibson.
Measurement and Modeling Issues with Adherence to Pharmacotherapy.
Presented at Academy of Managed Care Pharmacy Educational
Conference, St. Louis, MO, October 14, 2010.Roebuck, M.C., J.N.
Liberman, M. Gemmill-Toyama, and T.A. Brennan. Value of Medication
Adherence in Chronic Vascular Disease: Fixed Effects Models of
Health Services Utilization and Cost. Presented at Biennial
Conference of American Society of Health Economists, Cornell
University, Ithaca, NY, June 21, 2010.Roebuck, M.C., D. Esposito,
M.W. Lewis, and J. Berger. Dollars to Doughnuts: Predicting
Prescription Drug Costs of Enrollees and the Medicare Program under
Part D. Presented at Academy Health Annual Research Meeting,
Seattle, WA, June 26, 2006. Received Best Abstract Award (out of
1,670 presentations).PROFESSIONAL AFFILIATIONSMember of: Academy
Health, American Economic Peer Reviewer for: Health Affairs, Health
Services Research,Association, American Society of Health
Economists Journal of Drug Issues, Journal of General Internal
Medicine,(Scientific Committee Member), International HealthJournal
of Managed Care Pharmacy (Editorial AdvisoryEconomics Association
(Scientific Committee Member), Board Member), Journal of Substance
Abuse Treatment.Intl Society for Pharmacoeconomics & Outcomes
Research